Immuno-Oncology Conference (IO) 360°

Meet with Q2 Solutions at the 2019 I-O 360° Conference, Booth #22, and learn how we can help you ensure that the right drug is used to treat the right patient at the right time

New York, NY | February 06, 2019 - February 08, 2019 | 07:30 - 18:30 Add to Calendar
Stay Informed Schedule a Meeting

About This Event

IO360˚ brings together stakeholders in the science and business communities interested in data-driven advancements in immuno-oncology to fight a wider range of cancers. 

Q2 Solutions’ industry leading central lab services are closely tailored to power immuno-oncology studiesacross the development continuum. We can help leverage latest cancer research and precision medicine industry findings, and design smarter clinical trials through a range of genomic services. 

Attend the presentation, given by Patrice Hugo, PhD, and Chief Scientific Officer, Q2 Solutions, on February 6th, on “Key Clinical Trial Lab Capabilities to Enable Immuno-Oncology Drug Development”. 

We look forward to meeting you in New York City.

Related Services:

Register for Event


Patrice Hugo, Ph.D.
Immunology; Chief Scientific Officer

Dr. Patrice Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and completed post-doctoral fellowships in Immunology at the Walter Elisa Hall Institute in Australia, and at the Howard Hughes Medical Institute in Denver, Colorado. He then became a Principal Investigator leading the T-lymphocyte Unit at the Montreal Clinical Research Institute with academic appointments at McGill University and Montreal University. Throughout his academic work, Dr. Hugo focused on T-lymphocyte differentiation, self-tolerance induction, and  leukemogenesis. He worked at PROCREA BioSciences and Caprion as Chief Scientific Officer and Executive Vice President R&D, respectively. Dr. Hugo was assigned as Chief Scientific Officer at Clearstone Central Laboratories later acquired by LabCorp and became Associate Vice President and Chief Scientist at LabCorp/Covance Central Laboratories Division. Dr. Patrice Hugo joined Q2 Solutions as Chief Scientific Officer where he currently leads the global scientific strategy and is responsible for the medical affairs and scientific activities of the Central Laboratories, and the Specialty Testing Centers of Excellence worldwide including Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Dr. Hugo has more than 75 peer-reviewed scientific publications. He also played an active role in a number of industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).

Updated as of January 2019.

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Biomarker Roadmap to Success

Develop a biomarker roadmap for a successful strategy in developing targeted therapies

The importance of bioinformatics in immuno-oncology development

Big data solutions and bioinformatics services for genomic insights

Read More